Amarantus Bioscience and Revvity Compared: Which Medical Stock is Better?

Analysts see more upside potential in Revvity shares compared to Amarantus Bioscience.

Apr. 19, 2026 at 11:25am

Got story updates? Submit your updates here. ›

An extreme close-up of intricately engineered banking and financial machinery in shades of steel grey, bronze, and chrome, conveying a sense of institutional power and stored wealth without using literal currency or charts.The complex inner workings of Revvity's diagnostic and life sciences technologies reflect the institutional strength and financial security of the medical technology leader.NYC Today

Amarantus Bioscience (OTCMKTS:AMBS) and Revvity (NYSE:RVTY) are both medical companies, but which is the better investment? This analysis compares the two stocks based on valuation, risk, earnings, profitability, institutional ownership, dividends, and analyst recommendations.

Why it matters

Investors looking to gain exposure to the medical technology sector must weigh the relative strengths and weaknesses of Amarantus Bioscience and Revvity to determine which stock better fits their investment goals and risk tolerance.

The details

Revvity has higher revenue and earnings than Amarantus Bioscience, and 86.7% of its shares are held by institutional investors compared to just 10.3% for Amarantus. Revvity also has a lower beta of 1.13, indicating it is less volatile than the overall market. Analysts give Revvity a stronger consensus rating and see more potential upside in the stock.

  • Amarantus Bioscience was formerly known as Amarantus Bioscience, Inc. and changed its name in April 2013.
  • Revvity, Inc. was previously known as PerkinElmer, Inc. and changed its name in April 2023.

The players

Amarantus Bioscience Holdings, Inc.

A biopharmaceutical company focused on developing diagnostic and therapeutic products in neurology, psychiatry, ophthalmology, and regenerative medicine.

Revvity, Inc.

A provider of health sciences solutions, technologies, and services in the Americas, Europe, and Asia, offering instruments, reagents, informatics, software, and other products for the diagnostics and life sciences markets.

Got photos? Submit your photos here. ›

The takeaway

While both Amarantus Bioscience and Revvity operate in the medical technology space, the data suggests Revvity is the stronger investment option based on its higher revenue, earnings, institutional ownership, and more favorable analyst sentiment.